Miguel Medina
#180,774
Most Influential Person Now
Researcher
Miguel Medina's AcademicInfluence.com Rankings
Miguel Medinacomputer-science Degrees
Computer Science
#11415
World Rank
#12094
Historical Rank
Machine Learning
#5228
World Rank
#5294
Historical Rank
Artificial Intelligence
#5634
World Rank
#5716
Historical Rank
Database
#8441
World Rank
#8835
Historical Rank
Download Badge
Computer Science
Miguel Medina's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Miguel Medina Influential?
(Suggest an Edit or Addition)Miguel Medina's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Neuronal membrane cholesterol loss enhances amyloid peptide generation (2004) (328)
- Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. (2002) (325)
- Polymerization of τ into Filaments in the Presence of Heparin: The Minimal Sequence Required for τ ‐ τ Interaction (1996) (322)
- Presenilin 1 interaction in the brain with a novel member of the Armadillo family (1997) (310)
- New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors (2012) (304)
- WIP regulates N-WASP-mediated actin polymerization and filopodium formation (2001) (287)
- Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. (2012) (251)
- New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
- RhoA/ROCK regulation of neuritogenesis via profilin IIa–mediated control of actin stability (2003) (235)
- What is the evidence that tau pathology spreads through prion-like propagation? (2017) (221)
- δ-catenin, an Adhesive Junction–associated Protein Which Promotes Cell Scattering (1999) (190)
- An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration (2018) (182)
- Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. (2005) (182)
- Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib* (2011) (173)
- Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. (1996) (164)
- Deconstructing GSK-3: The Fine Regulation of Its Activity (2011) (155)
- Hemizygosity of δ-Catenin (CTNND2) Is Associated with Severe Mental Retardation in Cri-du-Chat Syndrome (2000) (153)
- Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. (2005) (146)
- Atypical, non-standard functions of the microtubule associated Tau protein (2017) (138)
- The role of extracellular Tau in the spreading of neurofibrillary pathology (2014) (133)
- Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice (2008) (127)
- New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. (2014) (123)
- Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. (2006) (119)
- MicroRNAs in Neurodegenerative Diseases. (2017) (119)
- An Overview on the Clinical Development of Tau-Based Therapeutics (2018) (118)
- Tissue plasminogen activator mediates amyloid‐induced neurotoxicity via Erk1/2 activation (2005) (110)
- Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. (2007) (106)
- Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies (2011) (99)
- Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
- Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. (2008) (84)
- δ‐catenin is a nervous system‐specific adherens junction protein which undergoes dynamic relocalization during development (2000) (81)
- Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. (2010) (81)
- Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome. (2000) (79)
- New Features about Tau Function and Dysfunction (2016) (71)
- C455R notch3 mutation in a Colombian CADASIL kindred with early onset of stroke (2002) (67)
- A δ-Catenin Signaling Pathway Leading to Dendritic Protrusions* (2008) (66)
- New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
- Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. (2016) (62)
- Ripped out by presenilin-dependent γ-secretase (2003) (61)
- Brain armadillo protein δ‐catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors (2002) (53)
- Presenilin Affects Arm/β-Catenin Localization and Function in Drosophila (2000) (50)
- Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. (2013) (49)
- New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease (2014) (48)
- Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors (2006) (43)
- Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine‐262 in the presence of heparin (or tubulin) (1995) (42)
- The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? (2019) (39)
- Potent β-Amyloid Modulators (2008) (38)
- Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment (2019) (36)
- Further understanding of tau phosphorylation: implications for therapy (2015) (35)
- RIPped out by presenilin-dependent gamma-secretase. (2003) (34)
- Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer disease and highlights potential translational opportunities (2020) (32)
- Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes (2013) (31)
- Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores (2019) (30)
- Recent developments in tau-based therapeutics for neurodegenerative diseases. (2011) (29)
- Residence, Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid (2021) (29)
- The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. (1996) (28)
- Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease (2015) (27)
- Role of tau N-terminal motif in the secretion of human tau by End Binding proteins (2019) (26)
- Toward common mechanisms for risk factors in Alzheimer's syndrome (2017) (26)
- Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus (2018) (25)
- The role of tau phosphorylation in transfected COS-1 cells (1995) (24)
- Dual binding site acetylcholinesterase inhibitors (2007) (24)
- Use of Okadaic Acid to Identify Relevant Phosphoepitopes in Pathology: A Focus on Neurodegeneration (2013) (24)
- Presenilin affects arm/beta-catenin localization and function in Drosophila. (2000) (22)
- Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls (2016) (15)
- The need for better AD animal models (2014) (15)
- Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro (2018) (14)
- Overcoming cell death and tau phosphorylation mediated by PI3K-inhibition: a cell assay to measure neuroprotection. (2011) (14)
- New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors (2012) (13)
- A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain. (2014) (11)
- Wnt-1 expression in PC12 cells induces exon 15 deletion and expression of L-APP (2004) (10)
- Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells. (1996) (10)
- Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk 1 / 2 activation (2005) (10)
- Is tau a prion-like protein? (2014) (9)
- Longitudinal assessment of a transgenic animal model of tauopathy by FDG-PET imaging. (2014) (9)
- Selective inhibition of cytokinesis in sea urchin embryos by the marine natural product pseudopterolide. (1992) (9)
- Presenilin 1 interaction in the brain with a novel member of the Armadillo family. (1997) (9)
- EuroTau: towing scientists to tau without tautology (2017) (8)
- Blood DNA Methylation Patterns in Older Adults With Evolving Dementia (2022) (7)
- Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins (2020) (7)
- Effects of Thioflavin T and GSK-3 Inhibition on Lifespan and Motility in a Caenorhabditis elegans Model of Tauopathy (2019) (6)
- Effects of commonly prescribed drugs on cognition and mild cognitive impairment in healthy elderly people (2019) (6)
- Detecting Circulating MicroRNAs as Biomarkers in Alzheimer's Disease. (2018) (5)
- Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors (2014) (5)
- Prodromal Alzheimer’s Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimer’s Pathology (2020) (5)
- Long runs of homozygosity are associated with Alzheimer’s disease (2021) (4)
- The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimer’s Disease (2011) (4)
- Long runs of homozygosity are associated with Alzheimer’s disease (2021) (4)
- Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study (2021) (3)
- Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks of AD: the GR@ACE project (2019) (3)
- A novel neuroprotection target with distinct regulation in stroke and Alzheimer’s disease (2017) (3)
- Tau Assembly into Filaments. (2018) (3)
- The in vitro formation of recombinant τ polymers (1996) (3)
- P4-428 TDZDS: GSK3β inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies (2004) (2)
- Recent developments in tau-based therapeutics for Alzheimer’s disease and related dementsia (2015) (2)
- Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus (2018) (2)
- Identification of protein kinases that modify specific epitopes. (1994) (2)
- Protocols for Monitoring the Development of Tau Pathology in Alzheimer's Disease. (2016) (2)
- Colocalization of Parkin with α-Synuclein in the Lewy Bodies of Parkinson Disease (2002) (1)
- Neuroanatomical signature of super‐ageing: Structural brain study of youthful episodic memory in people over the age of 80 (2020) (1)
- What is the evidence that tau pathology spreads through prion-like propagation? (2017) (1)
- The Dimensional Structure of Subjective Cognitive Decline (2018) (1)
- P2-402: A novel, highly specific glycogen synthase kinase-3 inhibitor of marine origin (2008) (1)
- Editorial: Untangling the Role of Tau in Physiology and Pathology (2020) (1)
- P4-335 Glycogen synthase kinase-3β inhibitors from marine origin (2006) (1)
- Atypical, non-standard functions of the microtubule associated Tau protein (2017) (1)
- 10 The Role of Glycogen Synthase Kinase-3 ( GSK-3 ) in Alzheimer ’ s Disease (2012) (0)
- Autosomal Recessive Alzheimer’s disease (arAD): homozygosity mapping of genomic regions containing arAD loci (2020) (0)
- The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? (2019) (0)
- δ-Catenin, Presenilin, and the Synaptic-Adherens Junction Complex (2002) (0)
- P2-103 GSK3β conditional transgenic mouse: a unique model for Alzheimer's disease and other tauopathies (2004) (0)
- Studies of the PS-1 pedigree from Columbia (2000) (0)
- 757 Posttranslational modifications of tau and the formation of paired helical filaments (1996) (0)
- A Novel Gene in the Armadillo Family Interacts with Presenilin 1 (1998) (0)
- A polygenic risk score for mosaic loss of chromosome Y susceptibility is associated with higher risk of MCI to AD conversion (2021) (0)
- Predicting the future development of mild cognitive impairment in the cognitively healthy elderly (2020) (0)
- P1-076 Effect of chronic lithium treatment on a transgenic mouse model of Alzheimer’s disease (2006) (0)
- The First Decade ( 1964-1972 ) Research Article (2018) (0)
- Marine neuroprotectants activating the alpha-secretase pathway: A novel approach for the treatment of Alzheimer's disease (2009) (0)
- White matter diffusion abnormalities observed in cognitively normal elderly before conversion to mild cognitive impairment (2021) (0)
- APOE ε4 effects on hippocampal atrophy in the healthy elderly reflect future cognitive decline (2022) (0)
- PROTECTION AGAINST SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT BY NOVEL CHOLINESTERASE INHIBITORS (2011) (0)
- WHITE MATTER LOSS IN THE HEALTHY ELDERLY BRAIN INDICATIVE OF IMPENDING COGNITIVE DECLINE (2017) (0)
- EuroTau: towing scientists to tau without tautology (2017) (0)
- Tau Phosphorylation as a Therapeutic Target in Alzheimer’s Disease (2016) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- P2-401: Potent marine neuroprotectants for the treatment of Alzheimer's disease (2008) (0)
- APOE‐ε4 and hippocampal volume in the cognitively healthy elderly: Longitudinal analysis reveals origins of apparent cross‐sectional differences (2020) (0)
- P1-106 Impaired learning ability in GSK3β-overexpressing transgenic mice (2006) (0)
- Protein Kinase Assays for Drug Discovery (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Miguel Medina?
Miguel Medina is affiliated with the following schools:
